137 related articles for article (PubMed ID: 36191975)
1. Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
Okabe KO; Terada N; Shirakawa T; Onizuka C; Kimura T; Yamashita Y; Otuka I; Ueno T; Nagano M; Takamori H; Mukai S; Kamoto T
Anticancer Res; 2022 Oct; 42(10):4981-4987. PubMed ID: 36191975
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673
[TBL] [Abstract][Full Text] [Related]
5. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
6. No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
Tanaka M; Kimura T; Iwamura Y; Enei Y; Iwamoto Y; Imai Y; Inaba Y; Matsukawa A; Onuma H; Ito K; Mori K; Sasaki H; Miki J; Furuta A; Miki K; Egawa S
Prostate; 2019 Oct; 79(14):1604-1610. PubMed ID: 31376184
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Chiang PC; Chiang PH; Chen IA; Chen YT; Wang HJ; Cheng YT; Kang CH; Chen CH; Liu YY; Su YL; Chen YH; Luo HL
Medicine (Baltimore); 2023 Feb; 102(5):e32671. PubMed ID: 36749250
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study.
Kandori S; Yoshino T; Tsutsumi M; Yamauchi A; Ohtani M; Fukuhara Y; Miyanaga N; Miyazaki J; Nishiyama H; Shimazui T
Prostate Int; 2016 Dec; 4(4):140-144. PubMed ID: 27995113
[TBL] [Abstract][Full Text] [Related]
10.
Boni G; Mazzarri S; Cianci C; Galli L; Farnesi A; Borsatti E; Bortolus R; Fratino L; Gobitti C; Lamaj E; Ghedini P; Rizzini EL; Massari F; Dionisi V; Fanti S; Volterrani D; Monari F
Tumori; 2018; 104(2):128-136. PubMed ID: 29714668
[TBL] [Abstract][Full Text] [Related]
11. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
13. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
14. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
15. Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.
Turco F; Tucci M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Audisio A; Audisio M; Parlagreco E; Ungaro A; Scagliotti GV; Di Maio M; Buttigliero C
Tumori; 2023 Apr; 109(2):233-243. PubMed ID: 35361017
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
17. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
18. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
19. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T; Sakano S; Matsuda K; Kamiryo Y; Yamamoto N; Kaneda Y; Nasu T; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Imoto K; Matsuyama H
Int J Clin Oncol; 2013 Feb; 18(1):62-7. PubMed ID: 22068464
[TBL] [Abstract][Full Text] [Related]
20. Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Caffo O; Frantellizzi V; Monari F; Galli L; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Donner D; Fanti S; Sbrana A; Morabito A; Masini C; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G
Cancer Biother Radiopharm; 2021 Jun; 36(5):391-396. PubMed ID: 33769088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
